Self‐Actuated Clot‐Piercing Nanoassembly Enabling Adaptable Drug Activation and Synergistic Thrombus Ablation DOI
Hongyuan Zhang, Sen Zhang, Shuwei Liu

et al.

Advanced Functional Materials, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 15, 2024

Abstract Clinical thrombus therapy continues to be challenged by unsatisfactory antithrombotic outcomes and high bleeding risk. Rational design of prodrugs for thrombolytic agents is expected ameliorate this situation. Nevertheless, a significant obstacle the inadequate penetration prodrug‐engineered nanomedicines, which hampers their effective interaction with excessive stimuli produced in thrombi, resulting suboptimal drug activation. Herein, clot‐piercing nanoassembly reported facilitate photothermal clot penetration, adaptable activation, anti‐inflammatory action, synergetic therapy, molecularly co‐assembled using photosensitizer reactive oxygen species (ROS)‐sensitive antiplatelet dimeric prodrug. The demonstrates multiple advantages, including facile fabrication, co‐loading capacity, long circulation time blood, thrombus‐targeting accumulation, photothermal‐potentiated deep on‐demand prodrug activation response H 2 O concentrations inside clots, anti‐inflammatory/antiplatelet synergy. These advantages result significantly enhanced efficacy vivo favorable safety. This study presents new paradigm development prodrug‐driven nanomedicines.

Language: Английский

Disulfide bond-driven nanoassembly of lipophilic epirubicin prodrugs for breast cancer therapy DOI

Haimeng Yuan,

Yao Chen, Yuting Hu

et al.

Journal of Pharmaceutical Investigation, Journal Year: 2025, Volume and Issue: unknown

Published: March 25, 2025

Language: Английский

Citations

1
Engineered cytomembrane nanovesicles trigger in situ storm of engineered extracellular vesicles for cascade tumor penetration and immune microenvironment remodeling DOI
Fei Sun, Shipeng Ning,

Xiaoyuan Fan

et al.

Nano Today, Journal Year: 2024, Volume and Issue: 61, P. 102604 - 102604

Published: Dec. 19, 2024

Language: Английский

Citations

4
A computer-aided, carrier-free drug delivery system with enhanced cytotoxicity and biocompatibility: a universal model for multifunctional lung cancer therapy DOI
Zhonglei Wang,

Wenjing Xu,

Shizeng Lei

et al.

Colloids and Surfaces B Biointerfaces, Journal Year: 2025, Volume and Issue: 250, P. 114557 - 114557

Published: Feb. 9, 2025

Language: Английский

Citations

0
The Potential of Nano-Formulated Natural Drugs in Melanoma Treatment: A Review of Pharmacological Efficacy and Mechanistic Insights DOI Creative Commons
Bowen Wang,

Yinan Wang

International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 3527 - 3539

Published: March 1, 2025

Melanoma is a very aggressive skin cancer; its treatment bears great challenges, hence the interest in new therapeutic approaches growing. In this review, potential nano-formulated natural drugs from plants such as Ginseng, Pistacia lentiscus, Amaranthus hypochondriacus, and Cannabis sativa of melanoma are discussed. We discuss various characteristics nanoformulations, including liposomes nanoemulsions, with respect to their ability enhancing drug delivery bioavailability. Key mechanisms action reactive oxygen species modulation, apoptotic signaling induction, immune modulation through TLR4/MyD88, inhibition angiogenesis by VEGF pathways Although these nanoformulations show promise improving outcomes, challenges related clinical application safety persist. Further research warranted fully explore how novel approach can best be utilized against melanoma.

Language: Английский

Citations

0
Construction of a programmed activation nanosystem based on intracellular hypoxia in cisplatin-resistant tumor cells for reversing cisplatin resistance DOI Creative Commons
Yurong Liu, Lei Si,

Yunheng Liu

et al.

Materials Today Bio, Journal Year: 2025, Volume and Issue: 32, P. 101709 - 101709

Published: March 27, 2025

Cancer poses a significant threat to human life and health. Cancers treated with cisplatin invariably develop drug resistance. This challenge can be overcome by identifying exploiting the vulnerabilities acquired drug-resistant cancer cells, paving way for finding effective novel treatment options cisplatin-resistant cancers. Our previous study revealed that resistance in cells comes at cost of increased intracellular hypoxia. In this study, we used 2-nitroimidazole modified hyaluronic acid (HA-NI) as carrier. The tumor cell specific hypoxia programmed activation nanomedicine (T/C@HN NPs) was constructed hypoxic toxic tirapazamine (TPZ) encapsulating chlorin e6 (Ce6) into HA-NI using polymer assembly technology. amphiphilic carrier could release free Ce6 molecules under stimulation environment, exhibit "activated state" photodynamic properties cells. Upon irradiation, Ce6-mediated therapy further intensifies hypoxia, amplifying its cytotoxicity. project systematically evaluated effects T/C@HN NPs on identification recognition tumors patient-derived xenograft (PDX) models. provides promising avenue development tumors.

Language: Английский

Citations

0
Self‐Actuated Clot‐Piercing Nanoassembly Enabling Adaptable Drug Activation and Synergistic Thrombus Ablation DOI
Hongyuan Zhang, Sen Zhang, Shuwei Liu

et al.

Advanced Functional Materials, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 15, 2024

Abstract Clinical thrombus therapy continues to be challenged by unsatisfactory antithrombotic outcomes and high bleeding risk. Rational design of prodrugs for thrombolytic agents is expected ameliorate this situation. Nevertheless, a significant obstacle the inadequate penetration prodrug‐engineered nanomedicines, which hampers their effective interaction with excessive stimuli produced in thrombi, resulting suboptimal drug activation. Herein, clot‐piercing nanoassembly reported facilitate photothermal clot penetration, adaptable activation, anti‐inflammatory action, synergetic therapy, molecularly co‐assembled using photosensitizer reactive oxygen species (ROS)‐sensitive antiplatelet dimeric prodrug. The demonstrates multiple advantages, including facile fabrication, co‐loading capacity, long circulation time blood, thrombus‐targeting accumulation, photothermal‐potentiated deep on‐demand prodrug activation response H 2 O concentrations inside clots, anti‐inflammatory/antiplatelet synergy. These advantages result significantly enhanced efficacy vivo favorable safety. This study presents new paradigm development prodrug‐driven nanomedicines.

Language: Английский

Citations

1